Abstract | BACKGROUND AND OBJECTIVES: DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: RESULTS: CONCLUSION:
|
Authors | Peter N Van Buren, Beverley Adams-Huet, Mark Nguyen, Christopher Molina, Robert D Toto |
Journal | Clinical journal of the American Society of Nephrology : CJASN
(Clin J Am Soc Nephrol)
Vol. 9
Issue 2
Pg. 295-301
(Feb 2014)
ISSN: 1555-905X [Electronic] United States |
PMID | 24408116
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Angiotensin II Type 1 Receptor Blockers
- Angiotensin-Converting Enzyme Inhibitors
- Biomarkers
- Diuretics
- Spironolactone
- Aldosterone
- Sodium
- Creatinine
- Lisinopril
- Losartan
- Potassium
|
Topics |
- Adult
- Aldosterone
(blood)
- Angiotensin II Type 1 Receptor Blockers
(adverse effects, therapeutic use)
- Angiotensin-Converting Enzyme Inhibitors
(adverse effects, therapeutic use)
- Biomarkers
(blood, urine)
- Creatinine
(urine)
- Diabetic Nephropathies
(blood, diagnosis, drug therapy, urine)
- Diuretics
(adverse effects, therapeutic use)
- Drug Therapy, Combination
- Female
- Humans
- Hyperkalemia
(blood, chemically induced)
- Lisinopril
(adverse effects, therapeutic use)
- Losartan
(adverse effects, therapeutic use)
- Male
- Middle Aged
- Potassium
(blood, urine)
- Prospective Studies
- Renin-Angiotensin System
(drug effects)
- Risk Factors
- Sodium
(urine)
- Spironolactone
(adverse effects, therapeutic use)
- Texas
- Time Factors
- Treatment Outcome
|